AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2019

Jun 25, 2019

Director's Dealing

Opens in your device viewer

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2019-06-21

Reporting Person: EQUELS THOMAS K. (Director, Exec. Vice Chairman/CEO/Pres.)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-21	Common Stock	P	29404	$4.03	Acquired	60409	Direct

F1: The amount of securities previously owned is being adjusted due to the 44 to 1 reverse stock split which occurred on June 11, 2019.